Susquehanna International Group’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-456,700
| Closed | -$101M | – | 13237 |
|
|
2025
Q4 | $101M | Buy |
456,700
+352,800
| +340% | +$57M | 0.01% | 884 |
|
|
2025
Q3 | $9.95M | Buy |
103,900
+50,100
| +93% | +$3.2M | ﹤0.01% | 3045 |
|
|
2025
Q2 | $2.62M | Buy |
+53,800
| New | +$1.29M | ﹤0.01% | 5245 |
|
|
2023
Q4 | – | Sell |
-1,000
| Closed | -$18.8K | – | 12417 |
|
|
2023
Q3 | $18.8K | Buy |
+1,000
| New | +$19.6K | ﹤0.01% | 11618 |
|
|
2021
Q4 | – | Sell |
-2,635
| Closed | -$118K | – | 13154 |
|
|
2021
Q3 | $118K | Buy |
2,635
+1,425
| +118% | +$54.1K | ﹤0.01% | 11958 |
|
|
2021
Q2 | $49K | Buy |
+1,210
| New | +$51.2K | ﹤0.01% | 12301 |
|
|
2020
Q4 | – | Sell |
-2,445
| Closed | -$139K | – | 11045 |
|
|
2020
Q3 | $139K | Sell |
2,445
-2,190
| -47% | -$155K | ﹤0.01% | 9733 |
|
|
2020
Q2 | $342K | Buy |
4,635
+3,355
| +262% | +$217K | ﹤0.01% | 8126 |
|
|
2020
Q1 | $63K | Buy |
+1,280
| New | +$76.7K | ﹤0.01% | 9570 |
|
|
2018
Q4 | – | Sell |
-1,115
| Closed | -$98K | – | 8994 |
|
|
2018
Q3 | $98K | Buy |
+1,115
| New | +$98.4K | ﹤0.01% | 8609 |
|
|
2018
Q2 | – | Sell |
-1,565
| Closed | -$125K | – | 9645 |
|
|
2018
Q1 | $125K | Buy |
+1,565
| New | +$214K | ﹤0.01% | 8610 |
|
Susquehanna International Group's CDTX Position: Q1 2026 in Review
Susquehanna International Group sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 2,388 shares — an estimated $527K sold.
Susquehanna International Group first reported a position in CDTX in Q2 2016 and held it in 15 quarters. The position peaked at $12.8M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Susquehanna International Group reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Susquehanna International Group sold 2,388 Cidara Therapeutics shares in Q1 2026, an estimated $527K.
- Susquehanna International Group first reported a position in Cidara Therapeutics in Q2 2016 and held it in 15 quarters.
- Susquehanna International Group's Cidara Therapeutics position peaked at $12.8M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.